A1 Refereed original research article in a scientific journal

Protein kinase C-activating isophthalate derivatives mitigate Alzheimer's disease-related cellular alterations




AuthorsSarajärvi T, Jäntti M, Paldanius {MA, Natunen T, Wu {C, Mäkinen P, Tarvainen I, Tuominen {K, Talman V, Hiltunen M

PublisherElsevier Scientific Publ. Co

Publication year2018

Journal: Neuropharmacology

Journal name in sourceNeuropharmacology

Volume141

ISSN0028-3908

DOIhttps://doi.org/10.1016/j.neuropharm.2018.08.020

Web address https://researchportal.helsinki.fi/en/publications/4bceb51d-d15c-4d26-97ea-92d0f831014e


Abstract
Abnormal protein kinase C (PKC) function contributes to many pathophysiological processes relevant for Alzheimer's disease (AD), such as amyloid precursor protein (APP) processing. Phorbol esters and other PKC activators have been demonstrated to enhance the secretion of soluble APP alpha (sAPP alpha), reduce the levels of beta-amyloid (A beta), induce synaptogenesis, and promote neuroprotection. We have previously described isophthalate derivatives as a structurally simple family of PKC activators. Here, we characterised the effects of isophthalate derivatives HMI-1a3 and HMI-1b11 on neuronal viability, neuroinflammatory response, processing of APP and dendritic spine density and morphology in in vitro. HMI-1a3 increased the viability of embryonic primary cortical neurons and decreased the production of the pro-inflammatory mediator TNF alpha, but not that of nitric oxide, in mouse neuron-BV2 microglia co-cultures upon LPS- and IFN-gamma-induced neuroinflammation. Furthermore, both HMI-1a3 and HMI-1b11 increased the levels of sAPPa relative to total sAPP and the ratio of A beta 42/A beta 40 in human SH-Sv5v neuroblastoma cells. Finally, bryostatin-1, but not HMI-1a3, increased the number of mushroom spines in proportion to total spine density in mature mouse hippocampal neuron cultures. These results suggest that the PKC activator HMI-1a3 exerts neuroprotective functions in the in vitro models relevant for AD by reducing the production of TNF alpha and increasing the secretion of neuroprotective sAPPa.



Last updated on 30/01/2026 03:57:31 PM